Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04101331 · ClinicalTrials.gov registry record · Phase 2
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
A Phase 2 study of Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides, sponsored by Affimed.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT04101331 is a Phase 2 study of Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides that has completed, run by Affimed. The registered enrollment target is 108 participants, roughly in line with the 103-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target. The trial reports 20 study locations across 11 states.
The verdict
NCT04101331, a Phase 2 study of Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides, has completed, sponsored by Affimed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as monotherapy in patients with CD30-positive T-cell lymphoma. The investigational medicinal product AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct which is being developed to treat CD30-positive malignancies. Patients who suffer from peripheral T-cell lymphoma or transformed mycosis fungoides, whose tumor expresses the surface marker CD30, and who have relapsed after an earlier treatment or have refractory disease will be enrolled into this study if all of the study entry criteria are fulfilled. Dependent on their disease type and the magnitude of CD30 expression, study participants will be assigned to one of 3 study cohorts, each cohort receiving the same treatment of weekly AFM13 infusions (a 200mg dose per infusion). The main goal of the study is to assess the efficacy of AFM13 treatment as judged by the rate of overall responses. Further goals are to assess the safety of AFM13 treatment, the immunogenicity of AFM13 (as measured by the potential formation of anti-AFM13 antibodies) and the concentration of AFM13 in the blood. Approx. 1 month after the last dose of AFM13 there will be a final study visit to assess the patients' health status after therapy, followed by quarterly phone contacts to check on their overall health status and long-term survival.
Conditions Studied
Interventions
- DRUG AFM13
Study Locations (20)
Other
- Royal Adelaide Hospital - Adelaide
- Flinders Medical Centre - Bedford Park
- Monash Health-Monash Medical Centre - Clayton
- Concord Repatriation General Hospital - Concord
- Gosford Hospital - Gosford
- Linear Clinical Research - Nedlands
- Centre Hospitalier Universitaire (CHU) de Bordeaux - Bordeaux
California
- City of Hope Comprehensive Cancer Center - Duarte
- University of California Los Angeles (UCLA) Health - Los Angeles
New York
- Center for Lymphoid Malignancies - New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Alabama
- University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center) - Birmingham
Georgia
- Emory University Clinic/Winship Cancer Institute - Atlanta
Louisiana
- Ochsner Clinic Foundation/Precision Cancer Therapies Program - New Orleans
Michigan
- University of Michigan Health | Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04101331
The ClinicalTrials.gov registry entry for NCT04101331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 103-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target. The listed sponsor is Affimed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AFM13 is the first listed.
NCT04101331 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04101331 about?
NCT04101331 is a clinical study titled "Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides". This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as monotherapy in patients with CD30-positive T-cell lymphoma. The investigational medicinal product AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct wh...
What is the current status of trial NCT04101331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2019-11-13. Estimated completion is 2024-01-11.
What conditions does trial NCT04101331 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Transformed Mycosis Fungoides.
What interventions are being tested in trial NCT04101331?
The interventions under investigation include: AFM13 (DRUG).
Who is sponsoring clinical trial NCT04101331?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04101331 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.